Home › Funds › Portolan Capital Management, LLC › UTHR

Portolan Capital Management, LLC position in UTHR

UNITED THERAPEUTICS CORP DEL · Health Care

Portolan Capital Management, LLC reported holding 119,939 shares of UTHR (UNITED THERAPEUTICS CORP DEL) in its Q3 2026 13F filing — a position valued at US$65.0M, representing 2.71% of its reported portfolio and ranking #4 among its reported holdings. Portolan Capital Management, LLC has disclosed UTHR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)119.94K sh
Reported value held$64.99M
Portfolio Weight2.71%
First reportedQ3 2023
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Portolan Capital Management, LLC's UTHR position evolved

Portolan Capital Management, LLC first disclosed a stake in UTHR in Q3 2023 at 81,048 shares (US$18.3M). The position peaked in Q3 2026 at 119,939 shares, worth US$65.0M. Across 13 filings, Portolan Capital Management, LLC increased the stake 7 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 119,939 shares valued at US$65.0M — an increase of 38,421 shares quarter over quarter.. Notable position changes include a 216% increase in Q1 2025 (shares fell 8% over the following quarter), a 103% increase in Q4 2025 (shares rose 22% over the following quarter), a 73% increase in Q1 2026 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 81.05K $18.31M New
Q4 2023 91.81K $20.19M Add
Q1 2024 110.92K $25.48M Add
Q2 2024 54.84K $17.47M Reduce
Q3 2024 30.51K $10.93M Reduce
Q4 2024 14.25K $5.03M Reduce
Q1 2025 45.07K $13.89M Add
Q2 2025 30.76K $8.84M Reduce
Q3 2025 18.08K $7.58M Reduce
Q4 2025 36.75K $17.91M Add
Q1 2026 63.44K $37.62M Add
Q2 2026 81.52K $44.17M Add
Q3 2026 119.94K $64.99M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About UTHR and 13F data

UTHR (UNITED THERAPEUTICS CORP DEL) is a Health Care company. 38 other funds we track also report a position in UTHR — the largest reported positions include Avoro Capital Advisors LLC (US$1.49B), Renaissance Technologies (US$908.2M), ASSETMARK, INC (US$325.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding UTHR

All UTHR fund holders →

FAQ

How long has Portolan Capital Management, LLC held UTHR?

Portolan Capital Management, LLC has disclosed UTHR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Portolan Capital Management, LLC's current position in UTHR?

As of Q3 2026, Portolan Capital Management, LLC holds 119.94K shares of UTHR (UNITED THERAPEUTICS CORP DEL), valued at $64.99M, representing 2.71% of its reported portfolio and ranking #4.

Has Portolan Capital Management, LLC been buying or selling UTHR?

In the latest 13F filing (Q3 2026), Portolan Capital Management, LLC increased its position in UTHR. The position peaked in Q3 2026 at 119.94K shares.

Which other funds hold UTHR?

Other major institutional holders of UTHR include Avoro Capital Advisors LLC, Renaissance Technologies, ASSETMARK, INC, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.